The Bull Rankings scorecard — our quality-growth score is 47.5 / 100, built from three pillars scored 0–100: Quality 80, Growth 70, Value 19 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free-cash-flow growth of about 20% a year next year, fading to 3% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
Johnson & Johnson’s current price of $267.08 sits on a foundation of quality that the Bull Rankings model rates at 80. That pillar is the heart of the case: a high‑quality compounder currently generating 21.5% profit margins and 24.8% ROE. The model’s 47.5/100 score is earned almost entirely by that quality, while the weak 19 in value simply reflects the premium the market already pays. In the quarter ended 2026‑06‑28, JNJ’s free‑cash‑flow of $22.2 b and a debt‑to‑equity of 0.58 show a cash‑rich, conservatively financed business. With a PE of 31 and a PEG of 4.38, the stock trades at a rich multiple, and the reverse‑DCF implies 20% free‑cash‑flow growth, well above recent revenue growth. That gap signals the price already demands faster growth than the company is delivering.
What the business actually is
Johnson & Johnson operates through two core segments. The Innovative Medicine arm delivers prescription products across oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular/metabolism. These drugs reach patients via retailers, wholesalers, distributors, hospitals, and healthcare professionals. The MedTech segment supplies surgical, orthopedic, cardiovascular, and vision devices to the same distribution network. The revenue engine is therefore a mix of high‑margin pharmaceuticals and medical devices, each with distinct growth drivers but both anchored in global healthcare demand.
Why it can (or can't) keep compounding
The durability case hinges on the company’s 21.5% profit margin, a healthy figure for a diversified drugmaker. Coupled with a ROE of 24.8%, JNJ turns equity into earnings efficiently. The beta of 0.23 means the stock has barely moved with the market. The model’s “Durable high returns” signal shows its returns on capital have held up for years rather than as a one‑off. Competitors struggle to replicate JNJ’s dual‑segment model: the breadth of therapeutic areas and the breadth of device markets create cross‑sell opportunities and a diversified risk profile that a single‑focus rival cannot match quickly.
The valuation question
At $267.08, the stock trades at a PE of 31 and a PEG of 4.38. The reverse‑DCF tells us that the current price implies ~20%/yr free‑cash‑flow growth (in year one, slowing to 3% a year by year ten). In contrast, the latest fiscal year shows 8.1% revenue growth. The implied growth far exceeds the actual revenue expansion, suggesting that the market is already pricing in a significant acceleration. If JNJ can lift revenue growth to the mid‑teens, the valuation would look justified; if it stalls, the premium may prove unsustainable. The market cap of $643.6 b and the current price also place the stock near its 52‑week high of $281.07, indicating that investors are already paying a premium for the quality narrative.
The bear case
The most compelling skeptic points to the PEG of 4.38. A PEG above 3 typically signals that earnings growth is not keeping pace with the price. If the company’s revenue growth fails to climb above 8.1% in the next year, the implied 20% free‑cash‑flow growth becomes untenable, and the premium evaporates. A concrete trigger would be a drop in the profit margin below 21.5%, which would erode the high‑margin advantage that fuels the quality score.
What would change our mind
- Revenue growth falling below 8.1% for two consecutive quarters would erode the growth narrative and tighten the PEG.
- A margin dip below 21.5% would signal cost pressures or pricing power erosion, weakening the quality pillar.
- If the debt‑to‑equity ratio climbed past 0.58, it would raise leverage concerns and potentially strain free‑cash‑flow generation.
Each of these thresholds would shift the balance from a quality‑driven bull case to a more cautious stance, prompting a reassessment of the implied growth assumptions embedded in the current price.